Πανελλήνιο Συνέδριο Καρκίνος Πνεύμονα Lung Cancer Network «From the Bench to the Bedside»

Επιλέξτε Μέρα

16-01-2020

Details: 17 βίντεο

17-01-2020

Details: 19 βίντεο

18-01-2020

Details: 24 βίντεο

46 E. Linardou - Lorlatinib in ALK+ NSCLC: the next step.

46 E. Linardou - Lorlatinib in ALK+ NSCLC: the next step.

47 S. Agelaki - Immunotherapy in 1st line NSCLC: from trials to practice.

47 S. Agelaki - Immunotherapy in 1st line NSCLC: from trials...

48 F. Grossi - I O combination in 1st line NSCLC - practice changing?

48 F. Grossi - I O combination in 1st line NSCLC - practice...

49 S. Gettinger - Immunotherapy in oncogene driven mNSCLC.

49 S. Gettinger - Immunotherapy in oncogene driven mNSCLC.

50 D. Rimm - Immunotherapy biomarkers beyond PD-L1.

50 D. Rimm - Immunotherapy biomarkers beyond PD-L1.

51 R. Pirker - The role of targeted therapies in early stages of NSCLC.

51 R. Pirker - The role of targeted therapies in early stage...

52 R. Pirker - Immunotherapy in mLCNEC: is there a role?

52 R. Pirker - Immunotherapy in mLCNEC: is there a role?

53 A. Passaro - Optimal therapeutic algorithm for mLCNEC patients.

53 A. Passaro - Optimal therapeutic algorithm for mLCNEC pat...

54 M. Erman - Molecular targets and therapies for SCLC.

54 M. Erman - Molecular targets and therapies for SCLC.

55 F. Detterbeck - Surgery for SCLC: is there a role?

55 F. Detterbeck - Surgery for SCLC: is there a role?

56 S. Gettinger - Phase I studies with novel immunotherapeutics.

56 S. Gettinger - Phase I studies with novel immunotherapeut...

57 V. Papadimitrakopoulou. - Novel combinations in I-O clinical trials.

57 V. Papadimitrakopoulou. - Novel combinations in I-O clini...

58 F. Barlesi - Optimal dosing and duration of I-O therapy.

58 F. Barlesi - Optimal dosing and duration of I-O therapy.

59 M. Garassino - Sequencing of I-O therapies.

59 M. Garassino - Sequencing of I-O therapies.

60 Discussion

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016

livemed white